MedTrace Logo

Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants

NCT06595706 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-03-05

No results posted yet for this study

Summary

This study aims to determine the safety and pharmacokinetics of multiple ascending doses of Lucid-21-302 in healthy adult participants.

Conditions

  • Heathy Participants

Interventions

DRUG

Lucid-21-302

Capsule containing a small molecule inhibitor of hypercitrullination

DRUG

Placebo

Capsule containing only Silicified Microcrystalline Cellulose

Sponsors & Collaborators

  • Huge Biopharma Australia Pty Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-28
Primary Completion
2025-01-24
Completion
2025-01-24

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06595706 on ClinicalTrials.gov